Australian medical research community leads innovation for patients affected by respiratory conditions
World events have placed the spotlight on respiratory health like never before. From severe bushfires to COVID-19, Australians living with respiratory conditions continue to face new health pressures.
Through the 2020/21 Investigator Sponsored Studies (ISS) program, GSK has committed a record of $6.9 million to continue supporting the health of Australians. More than 14 Australian research teams will be conducting studies in respiratory medicine, vaccines and oncology with the aim of improving health outcomes for patients.
Dr Andrew Weekes, Medical Director at GSK Australia, says that the ISS program funds researcher-initiated studies that have the potential to impact medical science and address unmet patient needs, especially in areas like respiratory diseases.
“These projects are entirely designed and managed by independent Australian research teams. This program enables us to extend our collaboration with medical researchers and support them as they work to accelerate scientific progress,” says Dr Weekes.
“Australian researchers competed globally for the program funding and ultimately represented 8% of the funded respiratory projects. Once again Australia is punching above its weight – reflecting the calibre of the local medical research community and the potential benefit for patients around the world.”
“We’re proud to be supporting so many research teams that share our passion for improving the lives of Australians with respiratory illnesses,” says Dr Weekes.
The current program sees GSK partnering with researchers from nine leading Australian institutions, including Griffith University, University of Melbourne, University of Newcastle and the Woolcock Institute of Medical Research.
Professor Sinthia Bosnic-Anticevich from the Woolcock Institute of Medical Research and the University of Sydney says the support provided by the GSK ISS program will help to propel research into raising the rate of specialist referrals for patients at risk of severe asthma.
“Australians living with asthma may only visit their GP once a year to update their personal care plan, but frequently visit a pharmacist to receive their medication and check their administration technique,” says Professor Bosnic-Anticevich.
“Our team is working with people living with asthma to understand their disease and referral history. Our findings will be used to produce a best practice guide to help pharmacists develop a well-defined and purposeful community referral pathway.”
“This study has the potential to improve patient identification and care for those suffering from severe asthma – like those patients with the highest burden of disease. With the support of the GSK ISS program, we’re able to bring it to life” says Professor Bosnic-Anticevich.
Dr Weekes says Australian academic research in respiratory disease has repeatedly challenged global thinking at the level of the cell, the person and the community. This has led to better diagnostic tools, more management paradigms and therapeutics.
“Studies like Professor Bosnic-Anticevich’s are outstanding examples of Australian innovation in practice; they challenge us all to do better in our approach to common respiratory conditions such as asthma,” says Dr Weekes.